1887

Abstract

We have previously constructed a recombinant adenovirus type 5 (Ad5) vector expressing the gD gene of pseudorabies virus (Ad-gD). In this virus the E1A gene was deleted, so that Ad-gD was replication defective. When high doses of this virus were inoculated into target species, it was nevertheless able to elicit a strong and protective immune response. We have restored a functional E1A gene in Ad-gD, by rescuing the E1A transcription unit in an ectopic position, far from the enhancer sequences of E1A. Unlike Ad-gD, this new virus (Ad-gD-E1A) was able to replicate in non-transcomplementing Vero cells. The kinetics of replication of Ad-gD-E1A were similar to that of the wild-type Ad5 when cells were infected at medium or high m.o.i. Nevertheless, the level of virus replication was low when Ad-gD-E1A was plated at low m.o.i. Cotton rats and mice were vaccinated once with 10 to 10 TCID of each of the two viruses. In both species, Ad-gD and Ad-gD-E1A induced similar antibody responses for each dose tested. Both were able to give a high level of protection against the challenge. However, the protective dose of Ad-gD-E1A was at least 250-fold lower in cotton rats, an Ad5-permissive species, than that of Ad-gD. In mice, a species restricted for Ad5 replication, the protective dose of Ad-gD-E1A was still not significantly different from that of Ad-gD. These data indicate that the protective dose of such an adenovirus vector vaccine for an animal species is strictly linked to the capacity of the virus to replicate in this species, at least in the model used. So, in designing an adequate vector one needs to balance the use of low dose vaccines against risks in terms of biosafety. Nevertheless, for diseases in which the protective immune response is mainly based on the antibody response, defective and non-defective adenovirus vectors should demonstrate similar protective doses.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-76-7-1583
1995-07-01
2021-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/76/7/JV0760071583.html?itemId=/content/journal/jgv/10.1099/0022-1317-76-7-1583&mimeType=html&fmt=ahah

References

  1. Adam M., Lepottier M. F., Eloit M. 1994; Vaccination of pigs with replication defective adenovirus: the example of pseudorabies. Veterinary Microbiology 42:205–215
    [Google Scholar]
  2. Ballay A., Levrero M., Tiollais P., Perricaudet M. 1987 In Hepdnaviruses – U,. C,. L,. A. Symposia on Molecular and Cellular Biology vol 70 pp 481–193 Edited by Robinson W., Koike K., Will H. New York: Alan R. Liss;
    [Google Scholar]
  3. Betts A. O., Jennings A. R., Lamont P. H., Page Z. 1962; Inoculation of pigs with adenovirus of man. Nature 193:45–16
    [Google Scholar]
  4. Brunet L. J., Berk A. J. 1988; Concentration dependence of transcriptional transactivation in inducible E1A-containing human cells. Molecular and Cellular Biology 8:4799–4807
    [Google Scholar]
  5. Caravokyri C., Pringle C. R., Leppard K. N. 1993; Human adenovirus type-5 recombinants expressing simian immunodeficiency virus macaque strain gag antigens. Journal of General Virology 74:2819–2824
    [Google Scholar]
  6. Charlton K. M., Artois M., Prevec L., Campbell J. B., Casey G. A., Wandeler A. I., Armstrong J. 1992; Oral vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Archives of Virology 123:169–179
    [Google Scholar]
  7. Chengalvala M. V., Bhat B. M., Bhat R., Lubeck M. D., Mizutani S., Davis A. R., Hung P. P. 1994; Immunogenicity of high expression adenovirus hepatitis B virus recombinant vaccines in dogs. Journal of General Virology 75:125–131
    [Google Scholar]
  8. Eloit M., Fargeaud D., L’Haridon R., Toma B. 1988; Identification of pseudorabies virus glycoprotein gp50 as a major target of neutralizing antibodies. Archives of Virology 99:45–56
    [Google Scholar]
  9. Eloit M., Bouzghaia H., Toma B. 1990; Identification of epitopes on the pseudorabies virus glycoprotein gp50 implicated in virus penetration of the host cell. Journal of General Virology 71:2179–2183
    [Google Scholar]
  10. Eloit M., Vannier P., Hutet E., Fournier A. 1992; Correlation between gl, gll, gill and gp50 antibodies and virus excretion in vaccinated pigs infected with pseudorabies virus. Archives of Virology 123:135–143
    [Google Scholar]
  11. Ganne V., Eloit M., Laval A., Adam M., Trouve G. 1993; Enhancement of the efficacy of a replication defective adenovirus vectored vaccine by the addition of oil adjuvants. Vaccine 12:1190–1196
    [Google Scholar]
  12. Graham F. L., Smiley J., Russell W. C., Nairn R. 1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology 36:59–72
    [Google Scholar]
  13. Gerard R. D., Meidell R. S. 1993; Adenovirus-mediated gene transfer. Trends in Cardiovascular Medicine 3:171–177
    [Google Scholar]
  14. Grable M., Hearing P. 1992; Cis and trans requirements for the selective packaging of adenovirus type 5 DNA. Journal of Virology 66:723–731
    [Google Scholar]
  15. Herbst R. S., Pelletier M., Boczo E. M., Babiss L. E. 1990; The state of cellular differentiation determines the activity of the adenovirus E1A enhancer element: evidence for negative regulation of enhancer function. Journal of Virology 64:161–172
    [Google Scholar]
  16. Hitt M. M., Graham F. L. 1990; Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. Virology 179:667–678
    [Google Scholar]
  17. Ishii H., Kobayashi Y., Kuroki M., Kodama Y. 1988; Protection of mice from lethal infection with Aujeszky’s disease virus by immunization with purified gVI. Journal of General Virology 69:1411–1414
    [Google Scholar]
  18. Jacobs S. C. 1993; A novel recombinant adenovirus vector expressing a flavivirus non-structural protein protects against lethal flavivirus challenge. Clinical Science 85:117–122
    [Google Scholar]
  19. Levrero M., Barban V., Manteca S., Ballay A., Balsamo C., Avantaggiati M. L., Natoli G., Skellekens H., Tiollais P., Perricaudet M. 1991; Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo . Gene 101:195–202
    [Google Scholar]
  20. Marchioli C., Yancey R., Petrovskis E., Timmins J., Post L. 1987; Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky’s disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells. Journal of General Virology 61:3977–3982
    [Google Scholar]
  21. Natuk R. J., Lubeck M. D., Chanda P. K., Chengalvala M., Wade M. S., Murthy S. C., Whilhelm J., Vernon S. K., Dheer S. K., Mizutani S. 1993; Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Research and Human Retroviruses 9:395–404
    [Google Scholar]
  22. Nevins J. R. 1990; Adenovirus E1A-dependent trans-activation of transcription. Seminars in Cancer Biology 1:59–68
    [Google Scholar]
  23. Oualikene W., Gonin P., Eloit M. 1994; Short and long term dissemination of deletion mutants of adenovirus in permissive (cotton rat) and non permissive (mouse) species. Journal of General Virology 75:2765–2768
    [Google Scholar]
  24. Prevec L., Schneider M., Rosenthal K. L., Belbeck L. W., Derbyshire J. B., Graham F. L. 1989; Use of human adenovirus-based vectors for antigen expression in animals. Journal of General Virology 70:429–134
    [Google Scholar]
  25. Prevec L., Campbell J. B., Christie B. S., Belbeck L., Graham F. L. 1990; A recombinant human adenovirus vaccine against rabies. Journal of Infectious Diseases 161:27–30
    [Google Scholar]
  26. Prevec L., Christie B. S., Laurie K. E., Bailey M. M., Graham F. L., Rosenthal K. L. 1991; Immune response to HIV-1 gag antigens induced by recombinant adenovirus in mice and rhesus macaque monkeys. Journal of Acquired Immune Deficiency Syndromes 4:568–576
    [Google Scholar]
  27. Prince G. A., Porter D. D., Jenson A. B., Horswood R. L., Chanock R. M., Ginsberg H. S. 1993; Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus). Journal of Virology 67:101–111
    [Google Scholar]
  28. Ragot T., Eloit M., Perricaudet M. 1991; Recombinant E1A-defective adenoviruses expressing pseudorabies and Epstein-Barr virus glycoproteins induce immunological responses as live vaccines in rabbits and mice. In Human Gene Transfer pp 249–260 Edited by Cohen-Haguenauer O., Boiron M. London: John Libbey;
    [Google Scholar]
  29. Ragot T., Finerty S., Watkins P. E., Perricaudet M., Morgan A. J. 1993; Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. Journal of General Virology 74:501–507
    [Google Scholar]
  30. SAS/STAT User’s guide, version 6 1989 4th edn SAS Institute Inc.; Cary NC:
  31. Ulmer J. B., Donnely J. H., Parker S. E., Rhodes G. H., Felgner P. H., Dwarki V. J., Gromhowski S. H., Deck R. R., Dewitt C. M., Friedman A., Hawe L. A., Leander K. R., Martinez D., Perry H. C., Shiver J. W., Montgomery D. L., Liu M. A. 1993; Fleterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745–1749
    [Google Scholar]
  32. Taylor J., Weiberg R., Tartaglia J., Richardson C., Alkhatib G., Briedis D., Appel M., Norton E., Paoletti E. 1992; Non replicating viral vectors as potential vaccines: recombinant canary-pox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 187:321–328
    [Google Scholar]
  33. Vernon S. K., Murthy S., Wilhem J., Chanda P. K., Kalyan N., Lee S. G., Hung P. P. 1991; Ultrastructural characterization of human immunodeficiency virus type 1 gag-containing particules assembled in a recombinant adenovirus vector system. Journal of General Virology 72:1243–1251
    [Google Scholar]
  34. Wesseling J. G., Godeke G. J., Schijns V. E. C. J., Prevec L., Graham F. L., Horzinek M. C., Rottier P. J. M. 1993; Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection. Journal of General Virology 74:2061–2069
    [Google Scholar]
  35. Zheng B. J., Graham F. L., Johnson D. C., Hanke T., McDermott M. R., Prevec L. 1993; Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 11:1191–1198
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-76-7-1583
Loading
/content/journal/jgv/10.1099/0022-1317-76-7-1583
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error